EP1128839A4 - Compositions pharmaceutiques comprenant des copolymeres de peptides synthetiques et methodes de prevention et de traitement de la reaction du greffon contre l'hote (gvhd) et de la reaction de l'hote contre le greffon (hvgd) - Google Patents

Compositions pharmaceutiques comprenant des copolymeres de peptides synthetiques et methodes de prevention et de traitement de la reaction du greffon contre l'hote (gvhd) et de la reaction de l'hote contre le greffon (hvgd)

Info

Publication number
EP1128839A4
EP1128839A4 EP99960378A EP99960378A EP1128839A4 EP 1128839 A4 EP1128839 A4 EP 1128839A4 EP 99960378 A EP99960378 A EP 99960378A EP 99960378 A EP99960378 A EP 99960378A EP 1128839 A4 EP1128839 A4 EP 1128839A4
Authority
EP
European Patent Office
Prior art keywords
hvgd
preventing
methods
pharmaceutical compositions
synthetic peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99960378A
Other languages
German (de)
English (en)
Other versions
EP1128839A1 (fr
Inventor
Rina Aharoni
Dvora Teitelbaum
Ruth Arnon
Michael Sela
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of EP1128839A1 publication Critical patent/EP1128839A1/fr
Publication of EP1128839A4 publication Critical patent/EP1128839A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP99960378A 1998-11-12 1999-11-12 Compositions pharmaceutiques comprenant des copolymeres de peptides synthetiques et methodes de prevention et de traitement de la reaction du greffon contre l'hote (gvhd) et de la reaction de l'hote contre le greffon (hvgd) Withdrawn EP1128839A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10818498P 1998-11-12 1998-11-12
US108184P 1998-11-12
US14521999P 1999-07-23 1999-07-23
US145219P 1999-07-23
PCT/US1999/027107 WO2000027417A1 (fr) 1998-11-12 1999-11-12 Compositions pharmaceutiques comprenant des copolymeres de peptides synthetiques et methodes de prevention et de traitement de la reaction du greffon contre l'hote (gvhd) et de la reaction de l'hote contre le greffon (hvgd)

Publications (2)

Publication Number Publication Date
EP1128839A1 EP1128839A1 (fr) 2001-09-05
EP1128839A4 true EP1128839A4 (fr) 2002-10-09

Family

ID=26805609

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99960378A Withdrawn EP1128839A4 (fr) 1998-11-12 1999-11-12 Compositions pharmaceutiques comprenant des copolymeres de peptides synthetiques et methodes de prevention et de traitement de la reaction du greffon contre l'hote (gvhd) et de la reaction de l'hote contre le greffon (hvgd)

Country Status (4)

Country Link
EP (1) EP1128839A4 (fr)
AU (1) AU775073C (fr)
CA (1) CA2355400A1 (fr)
WO (1) WO2000027417A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527760T3 (es) 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
EP1098902A4 (fr) 1998-07-23 2002-07-24 Yeda Res & Dev Traitement de maladies auto-immunes a l'aide du copolymere 1 et des copolymeres et peptides apparentes
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
ZA200206457B (en) 2000-02-18 2003-08-13 Yeda Res & Dev Oral, nasal and pulmonary dosage formulations of copolymer 1.
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2002076503A1 (fr) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Traitement de maladies du systeme nerveux central au moyen d'anticorps diriges contre l'acetate de glatiramere
NZ533327A (en) 2001-12-04 2006-11-30 Teva Pharma Processes for the measurement of the potency of glatiramer acetate
WO2004064717A2 (fr) * 2003-01-21 2004-08-05 Yeda Research And Development Co. Ltd. Copolymere 1 pour le traitement de maladies enteriques inflammatoires
CA2565819A1 (fr) * 2004-05-07 2005-12-01 Peptimmune, Inc. Methodes de traitement de maladies par copolymeres aleatoires
US7655221B2 (en) 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
HUE028833T2 (en) * 2004-09-09 2017-01-30 Yeda Res & Dev Polypeptide mixtures, compositions containing them, process for their preparation, and applications
KR101317131B1 (ko) 2004-09-09 2013-10-10 테바 파마슈티컬 인더스트리즈 리미티드 정제된 브롬화 수소산을 이용한 폴리펩타이드류의 혼합물의제조방법
JP5297653B2 (ja) 2004-10-29 2013-09-25 サンド・アクチエンゲゼルシヤフト グラチラマーの製造法
US20080171070A1 (en) * 2005-01-31 2008-07-17 Pierre Schaaf Polyelectrolyte Multilayer Film, Preparation And Uses Thereof
JP2009536157A (ja) 2006-04-13 2009-10-08 ペプチミューン，インコーポレイテッド エピトープ透過性の指向された拡張を介した指向性配列ポリマー組成物の設計方法および合成方法
EP2586460A1 (fr) 2007-10-16 2013-05-01 Peptimmune, Inc. Procédé de conception et de préparation de vaccins comprenant une composition polymère à séquence dirigée par expansion dirigée d'épitopes
DE202010018377U1 (de) 2009-08-20 2016-02-25 Yeda Research And Development Co., Ltd. Niedrigfrequente therapie mit glatirameracetat
JP5916622B2 (ja) 2010-01-04 2016-05-11 マピ ファーマ リミテッド グラチラマーまたはその薬理学的に許容される塩を含むデポーシステム
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8377885B2 (en) 2010-01-04 2013-02-19 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
KR20140019296A (ko) 2010-10-11 2014-02-14 테바 파마슈티컬 인더스트리즈 리미티드 글라티라머 아세테이트에 대한 임상 반응의 예측성 바이오마커로서의 사이토카인 바이오마커
ES2601892T3 (es) 2011-04-21 2017-02-16 Mapi Pharma Limited Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
EP2765857A4 (fr) 2011-10-10 2015-12-09 Teva Pharma Polymorphismes de nucléotide simple utiles pour prédire une réponse clinique à l'acétate de glatiramère
US9617596B2 (en) 2012-10-10 2017-04-11 Teva Pharmaceutical Industries, Ltd. Biomarkers predictive for clinical response for glatiramer acetate
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
US11167003B2 (en) 2017-03-26 2021-11-09 Mapi Pharma Ltd. Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992002543A1 (fr) * 1990-08-01 1992-02-20 Cytel Corporation Nouveaux peptides immunosuppresseurs
WO1994026774A1 (fr) * 1993-05-19 1994-11-24 Cytel Corporation Nouveaux traitements de maladies allergiques
WO1995026980A2 (fr) * 1994-04-01 1995-10-12 Immulogic Pharmaceutical Corporation Peptides haptines et leurs utilisations
WO1995031997A1 (fr) * 1994-05-20 1995-11-30 UNITED STATES OF AMERICA, represented by THE SECRETARY OF THE ARMY Modele destine a l'essai de l'immunogenicite des peptides
WO1996032119A1 (fr) * 1995-04-14 1996-10-17 Yeda Research And Development Co. Ltd. Compositions pharmaceutiques comportant un copolymere peptidique de synthese et servant a la prevention des troubles dus a la reaction greffe contre hote

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4339431A (en) * 1980-12-31 1982-07-13 Colgate-Palmolive Company Anticalculus oral composition
FR2658076B1 (fr) * 1990-02-12 1992-06-12 Sanofi Sa Composition cosmetique contenant des copolymeres d'aminoacides, utile comme agent hydratant.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992002543A1 (fr) * 1990-08-01 1992-02-20 Cytel Corporation Nouveaux peptides immunosuppresseurs
WO1994026774A1 (fr) * 1993-05-19 1994-11-24 Cytel Corporation Nouveaux traitements de maladies allergiques
WO1995026980A2 (fr) * 1994-04-01 1995-10-12 Immulogic Pharmaceutical Corporation Peptides haptines et leurs utilisations
WO1995031997A1 (fr) * 1994-05-20 1995-11-30 UNITED STATES OF AMERICA, represented by THE SECRETARY OF THE ARMY Modele destine a l'essai de l'immunogenicite des peptides
WO1996032119A1 (fr) * 1995-04-14 1996-10-17 Yeda Research And Development Co. Ltd. Compositions pharmaceutiques comportant un copolymere peptidique de synthese et servant a la prevention des troubles dus a la reaction greffe contre hote

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
AHARONI RINA ET AL: "Studies on the mechanism and specificity of the effect of the synthetic random copolymer GLAT on graft-versus-host disease.", IMMUNOLOGY LETTERS, vol. 58, no. 2, 1997, pages 79 - 87, XP002205821, ISSN: 0165-2478 *
FRIDKIS-HARELI M. ET AL.: "Binding of random copolymers of three aminoacids to class II MHC molecules", INTERNATIONAL IMMUNOLOGY, vol. 11, no. 5, May 1999 (1999-05-01), pages 635 - 641, XP000893153 *
FRIDKIS-HARELI M. ET AL.: "Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility comples molecules on living antigen-presenting cells - specificity and promiscuity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 91, 1994, WASHINGTON US, pages 4872 - 4876, XP000891508 *
LI Q. ET AL.: "Glatiramer acetate blocks the activation of THP-1 cells by interferon-gamma", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 342, 1998, pages 303 - 310, XP000893154 *
SCHLEGEL P G ET AL: "A SYNTHETIC RANDOM BASIC COPOLYMER WITH PROMISCUOUS BINDING TO CLASS II MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULES INHIBITS T-CELLPROLIFERATIVE RESPONSES TO MAJOR AND MINOR HISTOCOMPATIBILITY ANTIGENS IN VITRO AND CONFERS THE CAPACITY TO PREVENT MURINE GRAFT-VERSUS-HOST DISEASE IN VIVO", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 93, no. 10, 14 May 1996 (1996-05-14), pages 5061 - 5066, XP000578029, ISSN: 0027-8424 *
See also references of WO0027417A1 *
SELA M ET AL: "SUPPRESSIVE ACTIVITY OF COP-1 IN EAE AND ITS RELEVANCE TO MULTIPLE SCLEROSIS", BULL. INST. PASTEUR, vol. 88, 1990, pages 303 - 314, XP002926272 *
TEITELBAUM D ET AL: "COPOLYMER 1 FROM THE LABORATORY TO FDA", ISRAEL JOURNAL OF MEDICAL SCIENCES, ISRAEL MEDICAL ASSOCIATION, TEL AVIV, IL, vol. 33, no. 4, April 1997 (1997-04-01), pages 280 - 284, XP002926268, ISSN: 0021-2180 *
TEITELBAUM D ET AL: "CROSS-REACTIONS AND SPECIFICITIES OF MONOCLONAL ANTIBODIES AGAINST MYELIN BASIC PROTEIN AND AGAINST THE SYNTHETIC COPOLYMER1", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 88, November 1991 (1991-11-01), pages 9528 - 9532, XP002949037, ISSN: 0027-8424 *
TEITELBAUM D ET AL: "SUPPRESSION OF EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS BY A SYNTHETIC POLYPEPTIDE", EUROPEAN JOURNAL OF IMMUNOLOGY, WEINHEIM, DE, vol. 1, 1971, pages 242,244,246,248, XP002926270, ISSN: 0014-2980 *
TEITELBAUM D ET AL: "SYNTHETIC COPOLYMER 1 INHIBITS HUMAN T-CELL LINES SPECIFIC FOR MYELIN BASIC PROTEIN", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 89, January 1992 (1992-01-01), pages 137 - 141, XP002924839, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
AU1727000A (en) 2000-05-29
WO2000027417A1 (fr) 2000-05-18
AU775073B2 (en) 2004-07-15
EP1128839A1 (fr) 2001-09-05
CA2355400A1 (fr) 2000-05-18
AU775073C (en) 2007-05-03

Similar Documents

Publication Publication Date Title
EP1128839A4 (fr) Compositions pharmaceutiques comprenant des copolymeres de peptides synthetiques et methodes de prevention et de traitement de la reaction du greffon contre l'hote (gvhd) et de la reaction de l'hote contre le greffon (hvgd)
IL127545A0 (en) Compositions and methods for administering borrelia DNA
IL138533A0 (en) Pharmaceutical compositions for prolonged peptide release and preparation method
ZA974268B (en) Ethylene copolymers and blend compositions
HUP9900935A3 (en) Antifungic and antibacterial peptide and process for preparation
EP1025165A4 (fr) Procede et compositions renfermant des copolymeres polyphenoliques
IL138888A0 (en) Pharmaceutical composition and combination preparation for immunosuppressive therapy
HUP0100082A3 (en) Thrombin inhibitor, peptide derivatives, pharmaceutical compositions comprising thereof and their use
HUP0000460A3 (en) Imidazopyridazines and pharmaceutical compositions thereof
IL140742A0 (en) Raloxifene and pharmaceutical composition comprising the same
IL125908A0 (en) Peptides and pharmaceutical compositions comprising same
SG71754A1 (en) Copolymer and copolymer composition
IL125262A0 (en) Synthetic peptides and pharmaceutical compositions comprising them
IL121329A (en) Pharmaceutical composition for the treatment of cancer comprising somatostatin2 and other peptides
HUT74745A (en) Pharmaceutical compositions containing p antagonist for treating pruritis, eye- and eyelid-acs and eye-and eyelid dysaesthesia
AU2001291994A1 (en) Dipeptide ligands of the npff receptor for treating pain and hyperalgesia
EP0987942A4 (fr) Composition pharmaceutique et procede d'utilisation
GB9606579D0 (en) Pharmaceutical composition and methods for the manufacture thereof
GB9623962D0 (en) Pharmaceutical composition
IL116976A0 (en) Synthetic peptides and pharmaceutical compositions comprising them
IL137076A0 (en) Bibapctitide-based pharmaceutical compositions for imaging and treating thrombi
EP0975610A4 (fr) Composes pharmaceutiques a base de tripeptides et de tetrapeptides
ZA9811105B (en) Cosmetic and pharmaceutical composition
HU9600327D0 (en) Pharmaceutical composition for treating or profilacting meteoropathy and different kinetoses
IL126009A0 (en) Synthetic peptides and pharmaceutical compositions comprising them

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010612

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07K 5/00 A, 7C 07K 7/00 B, 7A 61K 38/00 B, 7C 07K 16/00 B, 7G 01N 33/53 B

A4 Supplementary search report drawn up and despatched

Effective date: 20020823

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20050818

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: YEDA RESEARCH AND DEVELOPMEMT CO., LTD.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: YEDA RESEARCH AND DEVELOPMENT CO., LTD.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20100427